UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

Cathie Sudlow1,2, John Gallacher3, Naomi Allen2,4, Valerie Beral4, Paul Burton6, John Danesh6, Paul Downey7, Paul Elliott7, Jane Green4, Martin Landray4, Bette Liu8, Paul Matthews7, Giok Ong9, Jill Pell10, Alan Silman11, Alan Young4, Tim Sprosen4, Tim Peakman2, Rory Collins2,4*

1 University of Edinburgh, Edinburgh, United Kingdom, 2 UK Biobank, Stockport, United Kingdom, 3 University of Cardiff, Cardiff, United Kingdom, 4 University of Oxford, Oxford, United Kingdom, 5 University of Bristol, Bristol, United Kingdom, 6 University of Cambridge, Cambridge, United Kingdom, 7 Imperial College, London, United Kingdom, 8 University of New South Wales, Sydney, Australia, 9 University of Warwick, Warwick, United Kingdom, 10 University of Glasgow, Glasgow, United Kingdom, 11 University of Manchester, Manchester, United Kingdom

* enquiries@ukbiobank.ac.uk

Summary Points

- UK Biobank is a very large and detailed prospective study with over 500,000 participants aged 40–69 years when recruited in 2006–2010.
- The study has collected and continues to collect extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometry, multimodal imaging, genome-wide genotyping and longitudinal follow-up for a wide range of health-related outcomes.
- Wide consultation; input from scientific, management, legal, and ethical partners; and industrial-scale, centralised processes have been essential to the development of this resource.
- UK Biobank is available for open access, without the need for collaboration, to any bona fide researcher who wishes to use it to conduct health-related research for the benefit of the public.

The challenge of understanding the determinants of common life-threatening and disabling conditions is substantial. These conditions are typically caused by a combination of lifestyle, environmental, and genomic factors, with individually modest effects and complex interactions, the detection and quantification of which require studies with large numbers of disease cases. While retrospective case-control studies of particular diseases [1] or existing prospective studies of particular risk factors can help to address this challenge [2,3], a complementary approach is to establish large prospective cohorts designed to study a much wider range of known and novel risk factors for a wide range of diseases [4]. Prospective studies can assess exposures before the onset and treatment of disease, diseases that are not readily investigated by
team or steering committee, or of one of UK Biobank’s working groups. PM is a part-time employee and holder of stock and options in GlaxoSmithKline and has received attendance fees and contributed to panels convened by the Medical Research Council, a public funder of UK Biobank. JD has received research funding from The Wellcome Trust, British Heart Foundation, UK Medical Research Council, BUPA Foundation, Denka, diaDexus, European Research Council, European Union, Evelyn Trust, Fogarty International Centre, GlaxoSmithKline, Merck, National Heart, Lung and Blood Institute, National Health Service Blood and Transplant, National Institute for Health Research, National Institute of Neurological Disorders and Stroke, Novartis, Pfizer, Roche, UK Biobank. RC is the CEO and PI of UK Biobank, which is a charity set up by the MRC and Wellcome Trust to establish this prospective cohort as a resource for researchers from around the world. RC is a member of the Editorial Board of PLOS Medicine. All other authors have declared that no competing interests exist.

Provenance: Not commissioned; externally peer reviewed

Table 1. Approximate numbers of incident cases of some exemplar conditions expected to accrue during the first 20 years of follow-up in UK Biobank.

<table>
<thead>
<tr>
<th>Condition</th>
<th>2012</th>
<th>2017</th>
<th>2022</th>
<th>2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus</td>
<td>10,000</td>
<td>25,000</td>
<td>40,000</td>
<td>68,000</td>
</tr>
<tr>
<td>MI and coronary death</td>
<td>7,000</td>
<td>17,000</td>
<td>28,000</td>
<td>47,000</td>
</tr>
<tr>
<td>Stroke</td>
<td>2,000</td>
<td>5,000</td>
<td>9,000</td>
<td>20,000</td>
</tr>
<tr>
<td>COPD</td>
<td>3,000</td>
<td>8,000</td>
<td>14,000</td>
<td>25,000</td>
</tr>
<tr>
<td>Breast cancer (female)</td>
<td>2,500</td>
<td>6,000</td>
<td>10,000</td>
<td>16,000</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>1,500</td>
<td>3,500</td>
<td>7,000</td>
<td>14,000</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>1,500</td>
<td>3,500</td>
<td>7,000</td>
<td>14,000</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>800</td>
<td>2,000</td>
<td>4,000</td>
<td>8,000</td>
</tr>
<tr>
<td>Hip fracture</td>
<td>800</td>
<td>2,500</td>
<td>6,000</td>
<td>17,000</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>800</td>
<td>2,000</td>
<td>3,000</td>
<td>5,000</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>800</td>
<td>3,000</td>
<td>9,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>1000</td>
<td>3,000</td>
<td>6,000</td>
<td>14,000</td>
</tr>
</tbody>
</table>

Based on UK age- and sex-specific rates with adjustment for healthy cohort effects and losses to follow-up [6].

MI: myocardial infarction; COPD: chronic obstructive pulmonary disease or chronic bronchitis/emphysema

doi:10.1371/journal.pmed.1001779.t001

UK (United Kingdom) Biobank is a very large, population-based prospective study, established to allow detailed investigations of the genetic and nongenetic determinants of the diseases of middle and old age [5,6]. It aims to combine extensive and precise assessment of exposures with comprehensive follow-up and characterisation of many different health-related outcomes, as well as to promote innovative science by maximising access to the resource. Recruitment of 500,000 participants and the collection of an unprecedented wealth of baseline data and samples were completed in 2010. Activity is now focused on further phenotyping of participants and their health outcomes and on providing access to researchers from around the world.

Cohort Size

The large size of the cohort was based on statistical power calculations for nested case-control studies [7], showing that 5,000–10,000 cases of any particular condition would be required for the reliable detection of odds ratios (ORs) for the main effects of different exposures of 1.3–1.5 (the upper end of the range reported from genome-wide association studies of various conditions [8]), and around 20,000 cases for detection of interactions with ORs of at least 2.0. To observe such large numbers of cases of particular diseases within a reasonable follow-up period, prospective cohorts need very large numbers of participants. Projected numbers of cases of a range of common conditions expected to occur among 500,000 UK Biobank participants during 20 years of follow-up (Table 1) suggest that reliable assessment of the main determinants of most of these conditions (and others that are similarly common) should be possible during the current decade [6,9]. The age range for inclusion of 40–69 years represented a pragmatic compromise between participants being old enough for there to be sufficient incident health outcomes during the early years of follow-up and young enough for the initial assessment to occur before incipient disease had a material impact on exposures.
Data Availability

Data from the Baseline Assessment

The 500,000 participants were assessed between 2006 and 2010 in 22 assessment centres throughout the UK, covering a variety of different settings to provide socioeconomic and ethnic heterogeneity and urban–rural mix. This ensured a broad distribution across all exposures to allow the reliable detection of generalisable associations between baseline characteristics and health outcomes. The assessment visit comprised electronic signed consent; a self-completed touch-screen questionnaire; brief computer-assisted interview; physical and functional measures; and collection of blood, urine, and saliva (Table 2). Multiple aliquots of different sample fractions are stored in UK Biobank’s automated laboratory, allowing for a wide range of future assays [10].

Data from Additional Assessments to Enhance Phenotyping

UK Biobank is conducting a range of additional phenotyping assessments in all (or large subsets) of the participants. Data are already available both from a detailed dietary web questionnaire [11], completed up to four times by over 200,000 participants, and from the first repeat of the entire baseline assessment in around 20,000 participants [12]. Over the coming months and years, further data will become available from: a range of biochemical assays and genome-wide genotyping of baseline samples from all participants; Web-based questionnaires to assess specific characteristics in more detail (e.g., cognitive function, occupational history); and, in subsets of 100,000 participants, collection of data from physical activity monitors and multi-modal imaging (Table 3).

Data from Longitudinal Follow-Up for Health-Related Outcomes

Follow-up is conducted chiefly through linkages to routinely available national datasets. Data are already available on over 8,500 deaths, over 75,000 prevalent and incident cancers, and over 600,000 hospital admissions, while linkages are planned to a range of other datasets, including primary care, cancer screening data, and disease-specific registers. In addition, to reduce misclassification and increase biological specificity of health outcomes, UK Biobank is developing methods for accurate identification and detailed phenotyping of outcomes in a range of disease areas. Initial ascertainment of outcomes with electronic and semi-automated sources will be supplemented by more intensive methods (e.g., retrieval of case records, imaging data, or banked tissue samples) for validation and subclassification (Table 3).

Online Open Access to Researchers

Many cohort studies have mechanisms for sharing data with external researchers on a collaborative basis, but relatively few have arrangements for open access to the data without any need for collaboration, and even fewer have been established from the outset with the intention of making the entire resource available to the global research community. The development of open access arrangements for data from cohort studies is an important step in maximising their impact with respect to scientific publications, policy making, and understanding of health and disease. Examples of resources whose impact has been enhanced in this way include the UK 1958 birth cohort study [13] and the Australian 45 and Up cohort study [14].

UK Biobank aims to encourage and provide as wide access as possible to its data and samples for health-related research in the public interest by all bona fide researchers from the academic, charity, public, and commercial sectors, both in the UK and internationally, without preferential or exclusive access for any user. UK Biobank’s publicly available Data Showcase (http://www.ukbiobank.ac.uk/) presents the univariate distributions and methods used for
collection of all the variables available for health-related research, enabling potential research users to explore what data are available and plan research applications.

An online access process, launched in April 2012, aims to be fair, transparent, and streamlined. Applications for data only are approved so long as the proposed research is in the public interest and the data required are, or will become, available. Applications involving the use of depletable samples or requiring participant re-contact are subject to a more rigorous process of scrutiny and scientific review. Following initial assessment by the executive team, all applications are assessed and either approved or rejected (with right of appeal) by an independent Access Subcommittee. Advice is sought on any applications raising potential ethical issues from both the University of Oxford’s Ethox Centre and the Ethics and Governance Council. Only de-identified data are provided to researchers, who must sign a material transfer agreement, undertaking not to attempt to identify any participant, to keep the data secure, and to use it only for the purposes of the approved research. Researchers must also undertake to publish their results and to return details of their methods, derived data, and/or sample assay results for incorporation into the UK Biobank dataset so that they can be made available to other approved researchers (see www.ukbiobank.ac.uk/scientists/ for details). UK Biobank encourages, but does not mandate, publication of results of research based on the resource in open access journals. Ensuring that the resource and its access arrangements are widely communicated is an important task, requiring a dedicated communications team to manage UK Biobank’s

### Table 2. Data collected at the baseline assessment.

<table>
<thead>
<tr>
<th>Questionnaire and interview</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sociodemographic</td>
</tr>
<tr>
<td>Family history and early life exposures</td>
</tr>
<tr>
<td>Psychosocial factors</td>
</tr>
<tr>
<td>Environmental factors</td>
</tr>
<tr>
<td>Lifestyle</td>
</tr>
<tr>
<td>Health status</td>
</tr>
<tr>
<td>Hearing threshold</td>
</tr>
<tr>
<td>Cognitive function</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physical measures</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure and heart rate</td>
<td>two automated measures, one minute apart</td>
</tr>
<tr>
<td>Grip strength</td>
<td>Left- and right-hand grip strength</td>
</tr>
<tr>
<td>Anthropometrics</td>
<td>Standing and sitting height; weight and bio-impedance; hip and waist circumference</td>
</tr>
<tr>
<td>Spirometry</td>
<td>Up to three measures</td>
</tr>
<tr>
<td>Bone density†</td>
<td>Calcaneal ultrasound</td>
</tr>
<tr>
<td>Arterial stiffness§</td>
<td>Pulse wave velocity</td>
</tr>
<tr>
<td>Eye examination†</td>
<td>Refractive index, intraocular pressure; acuity; retinal photograph; optical coherence tomography</td>
</tr>
<tr>
<td>Fitness test§</td>
<td>Cycle ergometry with electrocardiogram (ECG) heart rate monitoring</td>
</tr>
</tbody>
</table>

* assessed in 170,000 participants;  
† assessed in 50,000 participants;  
‡ measured in one heel for 170,000 participants and in both heels for 320,000 participants;  
§ measured in 170,000 participants;  
¶ measured in 100,000 participants  
§§ measured in 100,000 participants

doi:10.1371/journal.pmed.1001779.t002
Table 3. Current and planned future data available in the UK Biobank resource.

<table>
<thead>
<tr>
<th>Data type</th>
<th>Number of participants</th>
<th>Details</th>
<th>Date of data acquisition</th>
<th>Date first available for research&lt;sup&gt;‡&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline assessment</strong></td>
<td>Whole cohort</td>
<td>Questionnaire, physical measures, samples (see Table 2); haematological assays done on fresh blood samples</td>
<td>2006–2010</td>
<td>Q2 2012</td>
</tr>
<tr>
<td>Repeat of baseline assessment</td>
<td>20,000–25,000</td>
<td>As above every few years, to allow correction for regression dilution due to measurement error and within person fluctuations in exposure levels&lt;sup&gt;[12]&lt;/sup&gt;.</td>
<td>2013–</td>
<td>Q3 2013</td>
</tr>
<tr>
<td>Biochemical assays (of baseline samples)</td>
<td>Whole cohort</td>
<td>Biomarkers with known disease associations (e.g., lipids for vascular disease), diagnostic value (e.g., HbA1c for diabetes), or ability to characterize phenotypes not otherwise well assessed (e.g., renal and liver function tests).</td>
<td>2014–2015</td>
<td>2015</td>
</tr>
<tr>
<td>Genotyping (of baseline samples)</td>
<td>Whole cohort</td>
<td>Dense genotyping chip with &gt;800,000 markers including: approximately 250,000 SNPs in a whole-genome array; approximately 200,000 markers covering CNV, loss of function, insertions, deletions, and previously identified risk factor or disease associations; approximately 150,000 exome markers covering a high proportion of non-synonymous coding variants with allele frequency &gt;0.02%.</td>
<td>2013–2015</td>
<td>2015</td>
</tr>
<tr>
<td>Dietary Web questionnaire</td>
<td>210,000</td>
<td>Automatically coded dietary recall questionnaire, providing estimates of nutrient intake. 80,000 respondents completed it three times.</td>
<td>2011–2012</td>
<td>Q2 2013</td>
</tr>
<tr>
<td>Other Web questionnaires</td>
<td>350,000 to be approached</td>
<td>Participants invited by email to provide additional information via Web questionnaires about exposures (e.g., occupation) and health outcomes (cognitive function, depression) that are not readily identified from health record linkages.</td>
<td>2014–</td>
<td>2015</td>
</tr>
<tr>
<td>Accelerometry</td>
<td>100,000</td>
<td>Wrist-worn tri-axial accelerometers record information on type, intensity, and duration of physical activity.</td>
<td>2013–2015</td>
<td>2015</td>
</tr>
<tr>
<td>Multimodal imaging</td>
<td>100,000</td>
<td>MRI brain, heart, and abdomen (for lipid distribution); ultrasound of carotid arteries; whole body DXA scan of bones and joints</td>
<td>Pilot phase: 2014–2015 Main phase: 2016–2019</td>
<td>2015</td>
</tr>
<tr>
<td>Health record linkage</td>
<td>Whole cohort</td>
<td>ICD-coded cause specific mortality</td>
<td>2006–</td>
<td>Q2 2013</td>
</tr>
<tr>
<td>Death registrations</td>
<td></td>
<td></td>
<td>1971–*</td>
<td>Q2 2013</td>
</tr>
<tr>
<td>Cancer registrations</td>
<td></td>
<td></td>
<td>1997–*</td>
<td>Q4 2013</td>
</tr>
<tr>
<td>Hospital inpatient episodes</td>
<td></td>
<td></td>
<td>2003–*</td>
<td>2015</td>
</tr>
<tr>
<td>Hospital outpatient episodes</td>
<td></td>
<td></td>
<td>Variable</td>
<td>2015</td>
</tr>
<tr>
<td>Primary care</td>
<td></td>
<td></td>
<td>Variable</td>
<td>Not yet determined</td>
</tr>
<tr>
<td>Other</td>
<td>Whole cohort</td>
<td>UK Biobank will obtain data from national mental health care, residential history, laboratory and disease audit datasets and is considering the value of further linkages (e.g., imaging, cancer screening, dental).</td>
<td>2015</td>
<td></td>
</tr>
<tr>
<td>Adjudicated health outcomes</td>
<td></td>
<td>Expert-led confirmation and subclassification of outcomes in a range of disease areas, including cancer, diabetes, heart disease, stroke, mental health, musculoskeletal, respiratory, neurodegenerative, and ocular disorders.</td>
<td>2015</td>
<td></td>
</tr>
</tbody>
</table>

Hb: haemoglobin; SNPs: single nucleotide polymorphisms; CNV: copy number variations; MRI: magnetic resonance imaging; DXA: dual-energy X-ray absorptiometry; ICD: International Classification of Diseases; OPCS: Office of Population Censuses and Surveys Classification of Interventions and Procedures

<sup>‡</sup> Future dates are estimated. Data available may be all or part of the relevant dataset.

<sup>*</sup> available from an earlier date from health record systems in Scotland

doi:10.1371/journal.pmed.1001779.t003
website, scientific meetings, and other methods for communication with the scientific community, including emails, newsletters, and other social media. In the first two years after the launch of open access to UK Biobank, over 1,000 researchers successfully registered, and over 200 applications were submitted (see www.ukbiobank.ac.uk/approved-research/ for a summary of research that is currently underway). Over 80% of registered researchers were from the UK and over 95% from academic rather than commercial institutions. Approximately 85% of applications were for data only, with few as yet requesting use of samples or participant re-contact. UK Biobank has now started to receive notifications of submitted abstracts and manuscripts based on the first few completed research projects. UK Biobank reviews its access procedures regularly, revising them in the light of experience and user feedback to make the process as streamlined as possible while remaining consistent with participant consent.

Running UK Biobank

Success so far in developing and enhancing the resource has relied on public willingness to participate in prospective research studies; close engagement with funders, government health departments, and the UK National Health Service; extensive consultation with the public, scientists, and a wide range of regulatory, legal, and ethics bodies; and the development of cost-effective and efficient methodological approaches. The most significant challenges to be overcome are the implementation of scientifically rigorous processes on a very large scale, sustaining the funding required to ensure the benefits of the resource are fully realised, obtaining approvals from multiple regulatory bodies in a frequently changing political and healthcare environment, and ensuring as wide as possible communication of the non-preferential, open access nature of the resource.

Interactions with Participants

Participant recruitment, retention, and engagement with enhancement projects has benefited from the willingness of very large numbers of British people to take part in observational research without the prospect of direct personal gain [15]. Participants spent an average of about two and a half hours at the recruitment visit. All gave broad consent to use of their anonymised data and samples for any health-related research, to be re-contacted for further substudies, and for UK Biobank to access their health-related records. Large subsets have subsequently completed Web-based questionnaires, agreed to wear a physical activity monitor, and repeated the entire baseline assessment. Of those who attended the first repeat assessment visit and provided feedback, 92% reported that they would be willing to travel for up to two hours for an imaging assessment visit lasting half a day. UK Biobank keeps its participants involved through providing progress updates via its website, with annual newsletters, and through its dedicated Participant Resource Centre (PRC), enabling them to continue to support the project and participate in research over the years ahead.

Interactions with Funding Bodies

Having established UK Biobank as a charitable company over a decade ago, the UK Medical Research Council and Wellcome Trust have provided the vast majority of its funding so far. These major funders have had the long-term vision to continue to invest substantially in its ongoing development as a global research resource, coordinating both the scientific review of major proposals for developments to the resource and contributions from other funding bodies, including the Department of Health, Scottish and Welsh Governments, North West Development Agency, British Heart Foundation, and Diabetes UK. Long-term funding is not
guaranteed, but depends on UK Biobank working in close partnership with its funders towards
the common goal of facilitating high-quality, cost-effective research that will improve the pub-
lic’s health. Crucial to this partnership is provision and joint discussion of regular updates on
progress against challenging milestones, new strategic goals, scientific opportunities, financial
plans, and use of the resource to generate new scientific knowledge.

Interactions with the UK’s Publicly Funded National Health Service
Participant recruitment relied on invitations being mailed to 9 million people whose contact
details were obtained from National Health Service (NHS) central registers. Large-scale epide-
miological studies in the UK benefit from the fact that 98% of the population is registered with
the NHS, which keeps detailed records on all of them from birth to death. Linkages to NHS
datasets provide the principal means of follow-up for health-related outcomes.

Industrial Scale, Centralised Processes
A key step in achieving the cost-effective recruitment, characterisation, and follow-up of
500,000 participants was the creation of an executive and advisory team with complementary
scientific and management skills and a coordinating centre dedicated to the generation of a re-
source for the scientific community. This facilitated the development of a centralised infra-
structure, bespoke information technology (IT) systems, and industrial approaches to
collection and processing of data and samples. For example, inviting potential participants via
individual general-practice groupings (an approach used by smaller UK population-based
studies) would have been impractical for a study of UK Biobank’s scale, so appropriate approv-
als were obtained to allow direct mailing of invitations using contact details held centrally by
the NHS. The recruitment process itself was coordinated centrally, with up to six assessment
centres being active at any one time during the recruitment phase. Staffing and equipment
needs were carefully configured to ensure the smooth flow of around 100 participants per day
through each assessment centre for six days per week. Biological samples were also processed
and handled centrally, requiring the development of bespoke laboratory information manage-
ment and automated robotic systems to facilitate rapid, error-free sample storage in, and ex-
traction from, the freezers (at rates of up to 1,500 samples per day) according to particular
sample and participant characteristics [16]. Each step of the recruitment, assessment, and sam-
ple handling process was first piloted, modified as necessary and monitored centrally, using
statistical methods to identify potential performance issues. Similar industrial-scale, centralised
processes have been or are being developed for the repeat assessment and imaging visits.

Governance Structure
UK Biobank’s Board of Directors has overall responsibility for its direction and management.
An Executive Management Team, with epidemiology, clinical, management, laboratory, legal,
and communications expertise, oversees the development and day-to-day management of the
resource and is responsible for the staff working on the study, most of them based at its coordi-
nating centre near Manchester, with others at the Universities of Oxford, Edinburgh, Cardiff,
and London. The executive team receives guidance from a Steering Committee of leading UK
scientists, supported by specialist working groups advising on baseline data collection, en-
hanced phenotyping, follow-up and outcomes adjudication, and an international perspective is
provided by an International Scientific Advisory Board (see S1 Consent Form and www.
ukbiobank.ac.uk/governance/). This governance structure has facilitated effective working be-
tween scientific and management disciplines, allowing UK Biobank to respond to advice from
a wide network of scientists on the most scientifically valuable design and development of the
resource, with project management and implementation being the responsibility of UK Biobank’s Executive Management Team and dedicated staff.

**Robust Ethics and Governance Framework**

UK Biobank has consulted widely not only with the scientific community but also with the public, its participants, and other interested parties [17,18]. This has informed the development of its Ethics and Governance Framework, which lays out its principles and policies [19], as well as its access procedures [20]. UK Biobank’s research ethics committee and Human Tissue Authority research tissue bank approvals mean that researchers wishing to use the resource do not need separate ethics approval (unless re-contact with participants is required). An independent Ethics and Governance Council oversees adherence to the Ethics and Governance Framework and provides advice on the interests of research participants and the general public in relation to UK Biobank.

In keeping with the informed consent given by its participants, UK Biobank does not generally provide feedback to individual participants about information derived from analyses of data or samples made following their assessment visits. Participants receive limited individual feedback in two areas. First, they receive a summary of standard measures (e.g., blood pressure, body mass index) at the end of each assessment visit and are encouraged to seek medical advice for results outside the normal range. Second, potentially serious incidental findings (i.e., those likely to threaten life span or have a major impact on quality of life) observed by study staff during these assessments (e.g., possible melanoma on exposed areas of skin) are brought to the attention of participants with encouragement to contact a relevant health professional. Similar feedback is occurring in the imaging substudy, with participants and their general practitioners informed of potentially serious incidental findings noticed by radiographers and confirmed by formal radiologist review. In addition, the overall findings and implications of results that derive from research using the UK Biobank resource are made available to researchers, participants, and the wider community so that they can influence public health strategies.

**Interactions with Regulatory Bodies**

The wide consultation, rigorous Ethics and Governance Framework, and Ethics and Governance Council oversight role have been essential in paving the way for UK Biobank to accomplish obtaining the multiple ethical and regulatory approvals required for participant recruitment, sample and data storage, linkages to routine health care data, enhancement studies, and the provision of access to data and samples for approved researchers. Substantial amounts of time, resources, patience, tenacity, and evidence of feasibility and/or acceptability from smaller scale pilot studies have also been required to provide regulatory bodies with the reassurance that they need of UK Biobank’s rigorous approach and commitment to protecting the interests of its participants within an acceptable legal and ethical framework.

**Conclusions**

The key lessons learned from establishing UK Biobank are that such large-scale studies require not only a clear scientific focus but also streamlined governance; effective working between academic and management disciplines; centralised infrastructure with industrial approaches to collection and processing of data and samples; close partnership with major funders; a wide network of scientific advisors; high-quality, pragmatic legal and ethical advice; and widespread public support [21]. The resource is now facilitating research by scientists from around the world who wish to investigate how different diseases are caused by the combination of lifestyle, environment, and genes, leading to improvements in prevention, diagnosis, and treatment.
Perhaps unsurprisingly, early use has been mainly, but not exclusively, by UK-based scientists. A major aim for the immediate future is to encourage applications from outside the UK. To facilitate this, UK Biobank is further developing its communications strategy to increase awareness of the resource and its access procedures worldwide.

**Supporting Information**

S1 Consent Form. (PDF)

S1 Text. UK Biobank Committees and Working Groups. (PDF)

**Author Contributions**

Wrote the first draft of the manuscript: CS JG NA GO RC. Contributed to the writing of the manuscript: CS JG NA VB PB JD PD PE JG ML BL PM GO JP AS AY TS TP RC. ICMJE criteria for authorship read and met: CS JG NA VB PB JD PD PE JG ML BL PM GO JP AS AY TS TP RC. Agree with manuscript results and conclusions: CS JG NA VB PB JD PD PE JG ML BL PM GO JP AS AY TS TP RC.

**References**


